We developed creative solutions to showcase value differentiation for a third-to-market GT ​

P4A were able to understand the unique challenge we were facing as the third gene therapy to market and were able to develop creative and practical solutions
Global Commercial​ Lead​

Client Challenge

Identify ways to maximize access for a GT expected to be the 3rd GT to market ​

A small biotech in Phase 2/3 development for a gene therapy targeting competitively intense disease was concerned about being the third gene therapy to market ​

They wanted advice on how to differentiate themselves from the competition and ensure they would still be reimbursed by payers ​

P4A Solution

We conducted a “life-changers” workshop to understand internal perception of the GT value versus their competition and potential “reasons to wait”​

This workshop formed the basis of the value story development for the GT, focusing on proactively addressing payer concerns on: ​
  • Uncertainties in long term efficacy 
  • Value drivers/ differentiators compared to the other GTs expected to launch first  
  • Reasons to wait for the third gene therapy to market
  • High upfront cost of a one-time therapy, especially when other GTs may already being reimbursed 

The Successful Outcome​

  • Developed a value story proactively addressing payer concerns around a third-to-market gene therapy ​
  • Recommended strategies and communication points to effectively differentiate the GT form the competition, to give stakeholders a “reason to wait” ​
  • Develop pragmatic and feasible recommendations for the phase III clinical trial design and feasible evidence collection strategies​

Need more details?

Do you want to learn more about the successful outcome for this case study? Are you interested in P4A Services or just want to say Hi?

Explore other case studies

P4A Services

For all access and Rare Disease related overview enquiries